Indirin Adverse Reactions

Propranolol Hydrochloride (Indirin) is usually well tolerated. In clinical studies, the possible adverse reactions reported are usually attributable to the pharmacological actions of propranolol. The following possible adverse reactions, listed by body system, have been reported.
Blood and Lymphatic System Disorders: thrombocytopaenia, agranulocytosis.
Immune System Disorder: angioedema.
Metabolism and Nutrition Disorders: hypoglycemia in neonates, infants, children, elderly patients, patients on hemodialysis, patients on concomitant antidiabetic therapy, patients with prolonged fasting and patients with chronic liver disease has been reported; changes in lipid metabolism (changes in blood concentrations of triglycerides and cholesterol); severe hypoglycemia may rarely lead to seizures or coma.
Psychiatric Disorders: sleep disturbances, nightmares, hallucinations, psychosis, mood changes, depression.
Nervous System Disorders: confusion, memory loss, paraesthesia, dizziness, isolated reports of myasthenia gravis like syndrome or exacerbation of myasthenia gravis have been reported, headache, seizure linked to hypoglycemia.
Eye Disorders: dry eyes, visual disturbance, conjunctivitis.
Cardiac Disorders: bradycardia, cold extremities, heart failure deterioration, precipitation of heart block, postural hypotension which may be associated with syncope, worsening of attacks of angina pectoris.
Vascular Disorders: Raynaud's phenomenon, exacerbation of intermittent claudication.
Respiratory, Thoracic and Mediastinal Disorders: breathlessness, bronchospasm may occur in patients with bronchial asthma or a history of asthmatic complaints, sometimes with fatal outcome; dyspnea.
Gastrointestinal Disorders: gastrointestinal disturbances such as nausea, vomiting, diarrhea; constipation; dry mouth.
Skin and Subcutaneous Tissue Disorders: purpura, alopecia, psoriasiform skin reactions, exacerbation of psoriasis, skin rashes; isolated cases of hyperhidrosis have been reported.
Musculoskeletal and Connective Tissue Disorder: arthralgia.
Renal and Urinary Disorders: reduced renal blood flow and GFR.
Reproductive System and Breast Disorder: impotence.
General Disorders and Administration Site Conditions: fatigue and/or lassitude (often transient), dizziness.
Discontinuance of the drug should be considered if, according to clinical judgment, the well-being of the patient is adversely affected by any of the reactions. Cessation of therapy with a beta-blocker should be gradual. In the rare event of intolerance manifested as bradycardia and hypotension, the drug should be withdrawn and, if necessary, treatment for overdosage instituted.